Summary:
This study is for Uncontrolled, Type 2 Diabetics currently using Semaglutide or Tirzepatide (Ozempic, Mounjaro or Zepbound) for at least 3 months. Have an A1c of 7.5-10.5. This is a 40-week study with 11 office visits, for an investigational medication that may help lower A1c along with current dose of Semaglutide or Tirzepatide- provide by the study.
Qualified Participants Must:
• Type 2 Diabetics currently using Semaglutide or Tirzepatide (Ozempic, Mounjaro or Zepbound) for at least 3 months. Have an A1c of 7.5-10.5. Some other oral diabetic medications may be allowed.
Qualified Participants May Receive:
Patients will receive at no cost: Study related labs, physicals and testing as well as your Semaglutide or Tirzepatide (Ozempic, Mounjaro or Zepbound) along with an investigational diabetic medication. Compensation for all study visits.